Cosmo Pharmaceuticals N.V (C43) - Total Assets
Based on the latest financial reports, Cosmo Pharmaceuticals N.V (C43) holds total assets worth €612.64 Million EUR (≈ $716.24 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cosmo Pharmaceuticals N.V - Total Assets Trend (2016–2025)
This chart illustrates how Cosmo Pharmaceuticals N.V's total assets have evolved over time, based on quarterly financial data. Also see C43 company net worth for the company's overall valuation and market capitalisation.
Cosmo Pharmaceuticals N.V - Asset Composition Analysis
Current Asset Composition (December 2025)
Cosmo Pharmaceuticals N.V's total assets of €612.64 Million consist of 29.9% current assets and 70.1% non-current assets. Review Cosmo Pharmaceuticals N.V debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 9.1% |
| Accounts Receivable | €24.14 Million | 3.9% |
| Inventory | €10.43 Million | 1.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €325.88 Million | 53.2% |
| Goodwill | €24.00 Million | 3.9% |
Asset Composition Trend (2016–2025)
This chart illustrates how Cosmo Pharmaceuticals N.V's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Cosmo Pharmaceuticals N.V stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cosmo Pharmaceuticals N.V's current assets represent 29.9% of total assets in 2025, a decrease from 42.2% in 2016.
- Cash Position: Cash and equivalents constituted 9.1% of total assets in 2025, down from 26.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 56.0% of total assets, an increase from 4.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 53.2% of total assets.
Cosmo Pharmaceuticals N.V Competitors by Total Assets
Key competitors of Cosmo Pharmaceuticals N.V based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
China | CN¥2.89 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
Cosmo Pharmaceuticals N.V - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.18 | 4.19 | 11.60 |
| Quick Ratio | 6.77 | 3.91 | 11.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €157.76 Million | €153.99 Million | €231.07 Million |
Cosmo Pharmaceuticals N.V - Advanced Valuation Insights
This section examines the relationship between Cosmo Pharmaceuticals N.V's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 1.62 |
| Asset Growth Rate (YoY) | -5.3% |
| Total Assets | €612.64 Million |
| Market Capitalization | $993.61 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cosmo Pharmaceuticals N.V's assets above their book value (1.62x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Cosmo Pharmaceuticals N.V's assets decreased by 5.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cosmo Pharmaceuticals N.V (2016–2025)
The table below shows the annual total assets of Cosmo Pharmaceuticals N.V from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €612.64 Million ≈ $716.24 Million |
-5.28% |
| 2024-12-31 | €646.77 Million ≈ $756.14 Million |
+22.95% |
| 2023-12-31 | €526.04 Million ≈ $615.00 Million |
-30.75% |
| 2022-12-31 | €759.59 Million ≈ $888.04 Million |
-5.71% |
| 2021-12-31 | €805.56 Million ≈ $941.79 Million |
+35.12% |
| 2020-12-31 | €596.16 Million ≈ $696.97 Million |
+1.88% |
| 2019-12-31 | €585.16 Million ≈ $684.11 Million |
-6.48% |
| 2018-12-31 | €625.69 Million ≈ $731.49 Million |
+25.65% |
| 2017-12-31 | €497.97 Million ≈ $582.18 Million |
+12.29% |
| 2016-12-31 | €443.47 Million ≈ $518.47 Million |
-- |
About Cosmo Pharmaceuticals N.V
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more